Pharvaris N.V. (PHVS)

NASDAQ

$30.95

$-0.14

(-0.45%)

Regular Market

Pharvaris N.V. (PHVS) Live Price Chart

Last updated: ⁦2026-10-21 17:42:20⁩. Prices reflect the latest regular market data. Stock price data is sourced from Massive.

Summary

Pharvaris N.V. (PHVS) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $30.95, with a market capitalization of $2.09B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $21.02 to $43.25. This page covers its latest market performance, valuation, price trends and company information.

Key Market Data

Market Cap	$2.09B
Open	$31.22
Day's High	$43.25
Day's Low	$1.77
Previous Close	$30.90
Volume	194.79K
Average Volume	779.21K
P/E Ratio	--
52-Week High	$43.25
52-Week Low	$21.02
Dividend Yield	--
Earnings Date	--

Pharvaris N.V. (PHVS) Stock Price Today

Pharvaris N.V. (PHVS) is currently trading at $30.95 as of 2026-10-21 17:41:00, up 0.16% ($0.05) from the previous close of $30.90

During today's regular trading session, PHVS has traded between $1.77 and $43.25, with a trading volume of 194.79K shares. The current price is near the upper end of today's range.

Pharvaris N.V. (PHVS) 7-Day Stock Price Change

Over the past seven days, Pharvaris N.V. (PHVS) moved from $30.89 to $30.95, representing a gain of 0.19% ($0.06).

The stock traded between $27.68 and $35.40 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.

The average daily volume was 794.94 thousand shares, up versus the previous seven-day period, indicating higher trading activity.

PHVS 52-Week Price Position

Position in Range: 44.7%

52W Low$21.02

52W High$43.25

PHVS is currently trading at $30.95, placing it 44.7% of the way from its 52-week low of $21.02 to its 52-week high of $43.25. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.

What is Pharvaris N.V. (PHVS)?

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.

Pharvaris N.V. Information

Employees	129
Exchange	NASDAQ
Company Website	https://www.pharvaris.com

How to Buy Pharvaris N.V. (PHVS) Stock on MEXC

Eligible investors can buy real shares of Pharvaris N.V. (PHVS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.

Step 1: Open and Verify Your RealStocks Account

Log in to the MEXC App, go to Trade → RealStocks, and select Open Account. Complete the required account-opening and identity verification process with MEXC's partner licensed broker.

Step 2: Transfer USDT to Your RealStocks Account

Go to Wallets → RealStocks and transfer USDT from your Spot Account to your RealStocks Account. RealStocks are quoted in USD, while account funding can be completed using USDT.

Step 3: Search for PHVS and Place Your Order

Open the RealStocks trading page and search for PHVS. Select a market or limit order, enter the price and quantity as required, review the order details, and submit your order. Once filled, the corresponding real shares will be held in your RealStocks Account.

Frequently Asked Questions (FAQ)

1.What is Pharvaris N.V. (PHVS) stock price today?

Pharvaris N.V. (PHVS) is currently trading at $ 30.95, up 0.16% ($0.05) from the previous close of $ 30.90. Intraday prices update in real time during regular trading hours.

2.Is PHVS stock going up or down today?

As of 2026-10-21 17:41:00, PHVS is trading at $ 30.95, up 0.16% ($0.05) from its previous close of $ 30.90. The stock has traded between $ 1.77 and $ 43.25 during today’s regular session. Past price movements do not guarantee future results.

3.What is PHVS pre-market price?

As of 2026-10-21 17:41:00, PHVS is trading at $ 30.70 in pre-market trading, down 0.65% ($0.20) from the previous close of $ 30.90. Pre-market prices reflect trading activity before the regular session opens and may experience lower liquidity and higher volatility.

4.What is PHVS after-hours price?

As of 2026-10-21 17:41:00, PHVS is trading at $ 30.91 in after-hours trading, up 0.02% ($0.01) from the regular-session close of $ 30.90. After-hours prices may differ from the regular session’s opening price due to lower liquidity and wider bid-ask spreads.

5.Is PHVS stock trading now?

PHVS trades on the NASDAQ exchange during regular hours, Monday through Friday, 9:30 AM to 4:00 PM ET, excluding public holidays. Pre-market and after-hours trading are also available through select brokers outside these hours.

6.Where does PHVS sit relative to its 52-week high and low?

Over the past 52 weeks, PHVS has traded between a low of $ 21.02 and a high of $ 43.25. At $ 30.95, the stock is positioned 44.7% of the way from its 52-week low to its 52-week high, providing context for its current price within the one-year trading range.

7.What sector is Pharvaris N.V. in?

Pharvaris N.V. (PHVS) operates in the -- sector. Sector classification helps investors compare it with companies exposed to similar market trends and competitive conditions.

8.What is Pharvaris N.V.'s market capitalization and where is it listed?

Pharvaris N.V. is listed on the NASDAQ exchange with a market capitalization of $ 2.09B. Market cap reflects the total market value of all outstanding shares and is commonly used to classify stocks by size.

9.How is PHVS valued in terms of P/E ratio and EPS?

PHVS trades at a P/E ratio of --, based on trailing-twelve-month EPS of --. P/E ratio compares the stock price to earnings per share and is a common starting point for assessing valuation relative to peers.

10.Does Pharvaris N.V. pay a dividend?

Pharvaris N.V. pays an indicated annual cash dividend of -- per share, with a current dividend yield of --% based on the latest share price. Dividend policies are subject to change at the board's discretion.